Alphabodies represent a major medical and commercial opportunity.
They could change the way we think about drug development.
Complix is focused on applying its unique Alphabody platform to create new biotherapeutics that can address a broad target universe of known but currently inaccessible drug targets. This unique capability enables Complix and its partners to develop new treatments for a range of diseases for which current therapeutic options are limited or non-existent.
Complix’ current focus is the development of Cell-Penetrating Alphabodies (CPABs), which tackle intracellular targets, particularly protein-to-protein interactions (PPIs) involved in cancer and autoimmune disease. These intracellular PPIs are currently among the most interesting disease targets from a drug development perspective but also the hardest to address with current drug classes.
PPIs are known to play a key role in the initiation and progression of major diseases such as cancer, autoimmunity, CNS and metabolic diseases. The ability of Alphabodies to act on such intracellular protein targets represents a major medical and commercial opportunity.
Complix plans to create its own pipeline of Alphabodies, initially in the cancer and autoimmune space, and develop them through to initial proof of concept using its own in-house expertise and resources.
The Company also intends to engage in collaborative deals for Alphabodies with selected corporate partners that can contribute specific disease target expertise or development capabilities.